Lenalidomide in adult T-cell leukaemia-lymphoma
Mené au Japon sur 14 patients atteints de leucémie/lymphome T récidivant (âge supérieur à 20 ans), cet essai de phase I évalue la dose maximale tolérée du lénalidomide
The acute and lymphoma subtypes of adult T-cell leukaemia-lymphoma are among the most difficult diseases to treat, largely due to the absence of highly effective therapies and their aggressive nature. This difficulty was shown in the International T-cell Lymphoma project, which reported a dismal 5-year overall survival of 14% for adult T-cell leukaemia-lymphoma, the lowest among the T-cell entities. Allogeneic stem-cell transplantation offers the potential for long-term remission for about 35% of patients who receive it; however many patients are unable to undergo such a procedure because of inadequate response to therapy.
The Lancet Haematology , commentaire, 2015